SAMH1_HUMAN - dbPTM
SAMH1_HUMAN - PTM Information in dbPTM
Basic Information of Protein
UniProt ID SAMH1_HUMAN
UniProt AC Q9Y3Z3
Protein Name Deoxynucleoside triphosphate triphosphohydrolase SAMHD1
Gene Name SAMHD1
Organism Homo sapiens (Human).
Sequence Length 626
Subcellular Localization Nucleus .
Protein Description Host restriction nuclease involved in defense response to virus. Has dNTPase activity and reduces cellular dNTP levels to levels too low for retroviral reverse transcription to occur. Blocks early-stage virus replication in dendritic and other myeloid cells. Likewise, suppresses LINE-1 retrotransposon activity. May play a role in mediating proinflammatory responses to TNF-alpha signaling. [PubMed: 18546154]
Protein Sequence MQRADSEQPSKRPRCDDSPRTPSNTPSAEADWSPGLELHPDYKTWGPEQVCSFLRRGGFEEPVLLKNIRENEITGALLPCLDESRFENLGVSSLGERKKLLSYIQRLVQIHVDTMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCHDLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQDGDVIAPLITPQKKEWNDSTSVQNPTRLREASKSRVQLFKDDPM
Overview of Protein Modification Sites with Functional and Structural Information
Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations Modification Substrate Peptides
&
Secondary Structure
ASA (%) Reference Orthologous
Protein Cluster
1Acetylation-------MQRADSEQ
-------CCCCCCCC
5.7019413330
6Phosphorylation--MQRADSEQPSKRP
--CCCCCCCCCCCCC
36.8328450419
10PhosphorylationRADSEQPSKRPRCDD
CCCCCCCCCCCCCCC
40.7830242111
11UbiquitinationADSEQPSKRPRCDDS
CCCCCCCCCCCCCCC
73.44-
18PhosphorylationKRPRCDDSPRTPSNT
CCCCCCCCCCCCCCC
11.7523401153
21PhosphorylationRCDDSPRTPSNTPSA
CCCCCCCCCCCCCCC
34.1623401153
23PhosphorylationDDSPRTPSNTPSAEA
CCCCCCCCCCCCCCC
53.3623401153
25PhosphorylationSPRTPSNTPSAEADW
CCCCCCCCCCCCCCC
23.9823927012
27PhosphorylationRTPSNTPSAEADWSP
CCCCCCCCCCCCCCC
36.3823927012
33PhosphorylationPSAEADWSPGLELHP
CCCCCCCCCCCEECC
15.0523927012
42PhosphorylationGLELHPDYKTWGPEQ
CCEECCCCCCCCHHH
18.1223927012
66 (in isoform 2)Ubiquitination-46.28-
66UbiquitinationFEEPVLLKNIRENEI
CCCCEECCCCCCCCC
46.2821890473
66 (in isoform 1)Ubiquitination-46.2821890473
74O-linked_GlycosylationNIRENEITGALLPCL
CCCCCCCCCCHHHCC
15.3823301498
84O-linked_GlycosylationLLPCLDESRFENLGV
HHHCCCHHHHHHCCC
41.7723301498
92PhosphorylationRFENLGVSSLGERKK
HHHHCCCCCHHHHHH
20.3223186163
93PhosphorylationFENLGVSSLGERKKL
HHHCCCCCHHHHHHH
37.6823403867
98UbiquitinationVSSLGERKKLLSYIQ
CCCHHHHHHHHHHHH
43.39-
99UbiquitinationSSLGERKKLLSYIQR
CCHHHHHHHHHHHHH
61.9621890473
99 (in isoform 1)Ubiquitination-61.9621890473
102PhosphorylationGERKKLLSYIQRLVQ
HHHHHHHHHHHHHHH
30.5328450419
103PhosphorylationERKKLLSYIQRLVQI
HHHHHHHHHHHHHHH
10.8820068231
138PhosphorylationLLVRIIDTPQFQRLR
HHEEECCCHHHHHHH
14.4728450419
146PhosphorylationPQFQRLRYIKQLGGG
HHHHHHHHHHHHCCC
19.6421712546
148 (in isoform 1)Ubiquitination-30.4521890473
148UbiquitinationFQRLRYIKQLGGGYY
HHHHHHHHHHCCCEE
30.4521890473
155PhosphorylationKQLGGGYYVFPGASH
HHHCCCEEECCCCCC
10.0121712546
278PhosphorylationQIVGPLESPVEDSLW
EEECCCCCCCCCCCC
41.7623403867
280 (in isoform 2)Ubiquitination-20.80-
283PhosphorylationLESPVEDSLWPYKGR
CCCCCCCCCCCCCCC
20.8723403867
287PhosphorylationVEDSLWPYKGRPENK
CCCCCCCCCCCCCCC
17.9423403867
288UbiquitinationEDSLWPYKGRPENKS
CCCCCCCCCCCCCCC
44.35-
294AcetylationYKGRPENKSFLYEIV
CCCCCCCCCHHHHHH
40.717234285
294 (in isoform 1)Ubiquitination-40.7121890473
294UbiquitinationYKGRPENKSFLYEIV
CCCCCCCCCHHHHHH
40.7121890473
295PhosphorylationKGRPENKSFLYEIVS
CCCCCCCCHHHHHHC
31.8724247654
304 (in isoform 1)Ubiquitination-39.4721890473
304UbiquitinationLYEIVSNKRNGIDVD
HHHHHCCCCCCCCHH
39.4721890473
312 (in isoform 1)Ubiquitination-41.6421890473
312UbiquitinationRNGIDVDKWDYFARD
CCCCCHHHHHHHHHH
41.6421890473
315PhosphorylationIDVDKWDYFARDCHH
CCHHHHHHHHHHHHH
9.68-
3322-HydroxyisobutyrylationIQNNFDYKRFIKFAR
CCCCCCHHHHHHHHH
42.55-
332SumoylationIQNNFDYKRFIKFAR
CCCCCCHHHHHHHHH
42.55-
384PhosphorylationKVGNIIDTMITDAFL
HHHHHHHHHHHHHHH
10.4820068231
387PhosphorylationNIIDTMITDAFLKAD
HHHHHHHHHHHHHCC
15.5120068231
405UbiquitinationEITGAGGKKYRISTA
EEECCCCCEEEEEEE
45.79-
4052-HydroxyisobutyrylationEITGAGGKKYRISTA
EEECCCCCEEEEEEE
45.79-
407PhosphorylationTGAGGKKYRISTAID
ECCCCCEEEEEEEEH
19.3730576142
419PhosphorylationAIDDMEAYTKLTDNI
EEHHHHHHHHHCCCC
7.3621060948
420PhosphorylationIDDMEAYTKLTDNIF
EHHHHHHHHHCCCCH
26.9930576142
432PhosphorylationNIFLEILYSTDPKLK
CCHHHHHHCCCHHHH
18.3926503514
433PhosphorylationIFLEILYSTDPKLKD
CHHHHHHCCCHHHHH
23.9226503514
434PhosphorylationFLEILYSTDPKLKDA
HHHHHHCCCHHHHHH
42.6426503514
446UbiquitinationKDAREILKQIEYRNL
HHHHHHHHHHHHHHH
55.6921890473
446 (in isoform 1)Ubiquitination-55.6921890473
455 (in isoform 1)Ubiquitination-42.0421890473
455UbiquitinationIEYRNLFKYVGETQP
HHHHHHHHHCCCCCC
42.0421890473
467UbiquitinationTQPTGQIKIKREDYE
CCCCCEEEEEHHHHH
34.0021890473
467SumoylationTQPTGQIKIKREDYE
CCCCCEEEEEHHHHH
34.0028112733
467 (in isoform 1)Ubiquitination-34.0021890473
469SumoylationPTGQIKIKREDYESL
CCCEEEEEHHHHHHC
44.7428112733
469SumoylationPTGQIKIKREDYESL
CCCEEEEEHHHHHHC
44.74-
478UbiquitinationEDYESLPKEVASAKP
HHHHHCCHHHHCCCC
70.84-
482PhosphorylationSLPKEVASAKPKVLL
HCCHHHHCCCCEEEE
41.84-
486 (in isoform 1)Ubiquitination-44.8221890473
486UbiquitinationEVASAKPKVLLDVKL
HHHCCCCEEEEEEEE
44.8221890473
492SumoylationPKVLLDVKLKAEDFI
CEEEEEEEECHHHEE
43.8928112733
507PhosphorylationVDVINMDYGMQEKNP
EEEECCCCCCCCCCC
12.06-
519PhosphorylationKNPIDHVSFYCKTAP
CCCCCEEEEEECCCC
13.6923401153
521PhosphorylationPIDHVSFYCKTAPNR
CCCEEEEEECCCCCC
5.8727080861
534UbiquitinationNRAIRITKNQVSQLL
CCEEEEEHHHHHHHC
42.91-
544UbiquitinationVSQLLPEKFAEQLIR
HHHHCCHHHHHHHHH
48.1921890473
544 (in isoform 1)Ubiquitination-48.1921890473
553PhosphorylationAEQLIRVYCKKVDRK
HHHHHHHHHHHCCHH
6.68-
560UbiquitinationYCKKVDRKSLYAARQ
HHHHCCHHHHHHHHH
40.11-
563PhosphorylationKVDRKSLYAARQYFV
HCCHHHHHHHHHHHH
12.8125367160
579PhosphorylationWCADRNFTKPQDGDV
HHHCCCCCCCCCCCE
45.42-
592PhosphorylationDVIAPLITPQKKEWN
CEEEEEECCCCCCCC
27.6119664994
595SumoylationAPLITPQKKEWNDST
EEEECCCCCCCCCCC
54.59-
596UbiquitinationPLITPQKKEWNDSTS
EEECCCCCCCCCCCC
63.82-
601O-linked_GlycosylationQKKEWNDSTSVQNPT
CCCCCCCCCCCCCHH
21.2623301498
601PhosphorylationQKKEWNDSTSVQNPT
CCCCCCCCCCCCCHH
21.2628450419
602PhosphorylationKKEWNDSTSVQNPTR
CCCCCCCCCCCCHHH
35.4628857561
603PhosphorylationKEWNDSTSVQNPTRL
CCCCCCCCCCCHHHH
26.1728450419
608PhosphorylationSTSVQNPTRLREASK
CCCCCCHHHHHHHHH
50.3028450419
616PhosphorylationRLREASKSRVQLFKD
HHHHHHHHHCHHCCC
34.8823186163
622SumoylationKSRVQLFKDDPM---
HHHCHHCCCCCC---
70.57-
622SumoylationKSRVQLFKDDPM---
HHHCHHCCCCCC---
70.5728112733

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)
Modified Location Modified Residue Modification Type of Upstream Proteins Gene Name of Upstream Proteins UniProt AC of Upstream Proteins Sources
278SPhosphorylationKinaseUL97P16788
PSP
592TPhosphorylationKinaseCDK1P06493
Uniprot
592TPhosphorylationKinaseCDK2P24941
PSP
592TPhosphorylationKinaseUL97P16788
PSP
-KUbiquitinationE3 ubiquitin ligaseDCAF1Q9Y4B6
PMID:23677995

Functions of PTM Sites
Modified Location Modified Residue Modification Function Reference
592TPhosphorylation

17081983
592TPhosphorylation

17081983
592TPhosphorylation

17081983
592TPhosphorylation

17081983

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Modified Location Modification Variant Position
(Distance <= 10)
Residue Change SAP Related Disease Reference

Oops, there are no SNP-PTM records of SAMH1_HUMAN !!

Protein-Protein Interaction
Interacting Protein Gene Name Interaction Type PPI Reference Domain-Domain Interactions
DCAF1_HUMANVPRBPphysical
22362772
DDB1_HUMANDDB1physical
22362772
VPX_SIVG1vpxphysical
22362772
A4_HUMANAPPphysical
21832049
VPX_SIVG1vpxphysical
23874389
IMB1_HUMANKPNB1physical
23874389
IF4B_HUMANEIF4Bphysical
22863883
GANAB_HUMANGANABphysical
22863883
PUR2_HUMANGARTphysical
22863883
HS105_HUMANHSPH1physical
22863883
PLAK_HUMANJUPphysical
22863883
PLOD2_HUMANPLOD2physical
22863883
ANM3_HUMANPRMT3physical
22863883
RANB3_HUMANRANBP3physical
22863883
RL24_HUMANRPL24physical
22863883
SF01_HUMANSF1physical
22863883
SPT5H_HUMANSUPT5Hphysical
22863883
TRM1_HUMANTRMT1physical
22863883
XPO7_HUMANXPO7physical
22863883
CCNA2_HUMANCCNA2physical
24623419
CDK2_HUMANCDK2physical
24623419
SKP2_HUMANSKP2physical
24623419
CDK1_HUMANCDK1physical
24623419
FA13B_HUMANFAM13Bphysical
25423367
SAMH1_HUMANSAMHD1physical
25423367
EF1A1_HUMANEEF1A1physical
25423367
ACTB_HUMANACTBphysical
25423367
RBX1_HUMANRBX1physical
25423367
CUL4A_HUMANCUL4Aphysical
25423367
CCNL2_HUMANCCNL2physical
25532805
2AAA_HUMANPPP2R1Aphysical
26496610
2A5E_HUMANPPP2R5Ephysical
26496610
SMRD2_HUMANSMARCD2physical
26496610
STX3_HUMANSTX3physical
26496610
SF01_HUMANSF1physical
26496610
AKA12_HUMANAKAP12physical
26496610
MTCL1_HUMANMTCL1physical
26496610
RGAP1_HUMANRACGAP1physical
26496610
KANL3_HUMANKANSL3physical
26496610
ZMAT3_HUMANZMAT3physical
26496610
SOGA1_HUMANSOGA1physical
26496610
RSBNL_HUMANRSBN1Lphysical
26496610
GSK3A_HUMANGSK3Aphysical
28514442
GSK3B_HUMANGSK3Bphysical
28514442
CDK2_HUMANCDK2physical
28514442
NAA10_HUMANNAA10physical
28514442
IMA1_HUMANKPNA2physical
24712655
VPX_HV2BEHIV2gp3physical
24712655
VPX_SIVG1vpxphysical
24712655

Drug and Disease Associations
Kegg Disease
There are no disease associations of PTM sites.
OMIM Disease
612952Aicardi-Goutieres syndrome 5 (AGS5)
614415Chilblain lupus 2 (CHBL2)
Kegg Drug
There are no disease associations of PTM sites.
DrugBank
There are no disease associations of PTM sites.
Regulatory Network of SAMH1_HUMAN

loading...

Related Literatures of Post-Translational Modification
Acetylation
ReferencePubMed
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT THR-592, AND MASS SPECTROMETRY.
Phosphorylation
ReferencePubMed
"Large-scale proteomics analysis of the human kinome.";
Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.;
Mol. Cell. Proteomics 8:1751-1764(2009).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33 AND THR-592, AND MASSSPECTROMETRY.
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT THR-592, AND MASS SPECTROMETRY.
"A quantitative atlas of mitotic phosphorylation.";
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.;
Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-592, AND MASSSPECTROMETRY.
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle.";
Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.;
Mol. Cell 31:438-448(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-592, AND MASSSPECTROMETRY.
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks.";
Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.;
Cell 127:635-648(2006).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-592, AND MASSSPECTROMETRY.

TOP